Recommended Topic Related To:

Ceenu

"The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

Multiple myeloma is a form of blood cancer that p"...

CeeNU

CeeNU

Ceenu Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

CeeNU (lomustine) is used to treat brain tumors and Hodgkin's disease, and is sometimes given with other cancer medications. It is a cancer (antineoplastic) medication. Common side effects include nausea/vomiting (may be severe), loss of appetite, diarrhea, and mouth/lip sores. Nausea and vomiting usually last for less than 24 hours, though loss of appetite can last for several days.

The recommended dose of CeeNU in adult and pediatric patients as a single agent in previously untreated patients is 130 mg/mē as a single oral dose every 6 weeks. CeeNU may interact with "live" vaccines. Tell your doctor all medications and supplements you use, and all vaccines you have recently received. During pregnancy, CeeNU should be used only when prescribed. It may harm a fetus. If you become pregnant or think you may be pregnant, inform your doctor. Women should use 2 forms of birth control while using this medication. Consult your doctor. It is unknown if this drug passes into breast milk. Breastfeeding while using this drug is not recommended.

Our CeeNU (lomustine) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Ceenu in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • signs of infection such as fever, chills, sore throat, easy bruising or bleeding;
  • wheezing, rapid breathing, feeling short of breath;
  • chest pain, dry cough, fever, feeling ill;
  • urinating less than usual or not at all;
  • confusion, mood changes, increased thirst;
  • swelling in your ankles or feet;
  • jaundice (yellowing of the skin or eyes); or
  • white patches or sores inside your mouth or on your lips.

Less serious side effects may include:

  • loss of appetite, nausea, vomiting;
  • temporary hair loss;
  • vision problems; or
  • feeling weak or tired.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Ceenu (Lomustine Capsules) »

What is Patient Information Overview?

A concise overview of the drug for the patient or caregiver from First DataBank.

Ceenu Overview - Patient Information: Side Effects

SIDE EFFECTS: Nausea, vomiting, loss of appetite, diarrhea, and mouth/lip sores may occur. Nausea and vomiting usually last for less than 24 hours, though loss of appetite can last for several days. Nausea and vomiting can be quite severe. In some cases, your doctor may prescribe medication to prevent/treat nausea and vomiting. Changes in diet such as eating several small meals or limiting activity may help decrease some of these effects. If these effects persist or worsen, notify your doctor or pharmacist promptly.

Temporary hair loss may occur. Normal hair growth should return after treatment has ended.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. (See also Warning section.)

Tell your doctor immediately if any of these unlikely but serious side effects occur: confusion, swelling of lower legs/feet, vision changes.

Tell your doctor immediately if any of these rare but very serious side effects occur: coughing up blood, persistent nausea/vomiting, stomach/abdominal pain, black tarry stools, unusual tiredness, change in the amount of urine, dark or pink urine, yellow eyes/skin.

A severe (sometimes fatal) lung problem (pulmonary fibrosis) has occurred in patients using this drug. This condition can occur months to years after you start taking this medication. Tell your doctor immediately if you experience any of these serious side effects: cough, chest pain, difficult/painful breathing.

A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Ceenu (Lomustine Capsules)»

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Ceenu FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

Hematologic Toxicity

The most frequent and most serious toxicity of CeeNU is delayed myelosuppression. It usually occurs 4 to 6 weeks after drug administration and is dose related. Thrombocytopenia occurs at about 4 weeks postadministration and persists for 1 to 2 weeks. Leukopenia occurs at 5 to 6 weeks after a dose of CeeNU and persists for 1 to 2 weeks. Approximately 65% of patients receiving 130 mg/m² develop white blood counts below 5000 wbc/mm³. Thirty-six percent developed white blood counts below 3000 wbc/mm³. Thrombocytopenia is generally more severe than leukopenia. However, both may be dose-limiting toxicities.

CeeNU may produce cumulative myelosuppression, manifested by more depressed indices or longer duration of suppression after repeated doses.

The occurrence of acute leukemia and bone marrow dysplasias have been reported in patients following long-term nitrosourea therapy.

Anemia also occurs, but is less frequent and less severe than thrombocytopenia or leukopenia.

Pulmonary Toxicity

Pulmonary toxicity characterized by pulmonary infiltrates and/or fibrosis has been reported rarely with CeeNU. Onset of toxicity has occurred after an interval of 6 months or longer from the start of therapy with cumulative doses of CeeNU usually greater than 1100 mg/m². There is 1 report of pulmonary toxicity at a cumulative dose of only 600 mg.

Delayed onset pulmonary fibrosis occurring up to 17 years after treatment has been reported in patients who received related nitrosoureas in childhood and early adolescence (1-16 years) combined with cranial radiotherapy for intracranial tumors. There appeared to be some late reduction of pulmonary function of all long-term survivors. This form of lung fibrosis may be slowly progressive and has resulted in death in some cases. In this long-term study of carmustine, all those initially treated at less than 5 years of age died of delayed pulmonary fibrosis.

Gastrointestinal Toxicity

Nausea and vomiting may occur 3 to 6 hours after an oral dose and usually last less than 24 hours. Prior administration of antiemetics is effective in diminishing and sometimes preventing this side effect. Nausea and vomiting can also be reduced if CeeNU is administered to fasting patients.

Hepatotoxicity

A reversible type of hepatic toxicity, manifested by increased transaminase, alkaline phosphatase, and bilirubin levels, has been reported in a small percentage of patients receiving CeeNU.

Nephrotoxicity

Renal abnormalities consisting of progressive azotemia, decrease in kidney size, and renal failure have been reported in patients who received large cumulative doses after prolonged therapy with CeeNU. Kidney damage has also been reported occasionally in patients receiving lower total doses.

Other Toxicities

Stomatitis, alopecia, optic atrophy, and visual disturbances, such as blindness, have been reported infrequently.

Neurological reactions, such as disorientation, lethargy, ataxia, and dysarthria have been noted in some patients receiving CeeNU. However, the relationship to medication in these patients is unclear.

Read the entire FDA prescribing information for Ceenu (Lomustine Capsules) »

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.

Related Supplements
advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations